On Jan. 22, 2021, Novavax announced that it had finalized an agreement with the Government of Canada to supply up to 76 million doses of NVX-CoV2373, the company’s recombinant protein-based COVID-19 vaccine. Canada committed to purchase 52 million doses of the vaccine with the option for up to an additional 24 million doses.

NVX-CoV2373 was in Phase 3 clinical development for the prevention of COVID-19.